Key terms

About ZNTL

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in New York, NY.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest ZNTL news

Apr 09 4:43pm ET Zentalis Pharmaceuticals to Present at Upcoming Conferences by TipRanks Apr 01 7:59am ET Immunome price target raised to $33 from $27 at Wedbush by TipRanks Mar 01 1:04am ET Zentalis Pharmaceuticals: A Cautious Hold Amidst Speculative Opportunities and Upcoming Clinical Updates by TipRanks Feb 29 5:19pm ET Zentalis files automatic mixed securities shelf by TipRanks Feb 28 8:48am ET Zentalis price target raised to $15 from $12 at Wedbush by TipRanks Feb 28 7:47am ET Oppenheimer Keeps Their Buy Rating on Zentalis Pharmaceuticals (ZNTL) by TipRanks Feb 28 6:38am ET Buy Rating Affirmed for Zentalis Pharmaceuticals on Strategic Positioning and Clinical Prospects in Ovarian Cancer Treatment by TipRanks Feb 28 5:43am ET Buy Rating on Zentalis Pharmaceuticals Amidst Undervalued Share Price and Promising Clinical Developments by TipRanks Feb 27 1:25pm ET TD Cowen Keeps Their Buy Rating on Zentalis Pharmaceuticals (ZNTL) by TipRanks Feb 27 7:06am ET Zentalis sees cash runway into 2026 by TipRanks Feb 27 7:05am ET Zentalis announces anticipated upcoming milestones by TipRanks Feb 27 7:03am ET Zentalis reports 2023 EPS ($4.47), consensus ($4.54) by TipRanks Feb 15 4:22pm ET Zentalis Pharmaceuticals Updates Bylaws for Enhanced Governance by TipRanks Jan 26 4:05am ET Zentalis Pharmaceuticals Issues Regulation FD Disclosure Statement by TipRanks Jan 26 4:05am ET Zentalis Pharmaceuticals Announces New Chief Medical Officer by TipRanks Jan 26 4:05am ET Zentalis Pharmaceuticals Faces Nasdaq Delisting Notice by TipRanks Jan 25 7:14am ET Zentalis appoints Hausman as CMO, Rasbach as CBO by TipRanks Jan 23 7:44am ET Immunome price target raised to $19 from $12 at Wedbush by TipRanks

No recent press releases are available for ZNTL

ZNTL Financials

1-year income & revenue

Key terms

ZNTL Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

ZNTL Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

A bubble tea store operated by Sichuan Baicha Baidao in Shanghai, China, on April 23, 2024.
Raul Ariano/Bloomberg/Getty Images
Is the tea bubble bursting? ChaPanda shares plunge in Hong Kong IPO
People walk past the New York Stock Exchange (NYSE) on April 10, 2024 in New York City.
Spencer Platt/Getty Images
Can markets make a comeback? That depends on tech earnings
People walk past the New York Stock Exchange Thursday, March. 21, 2024.
Yuki Iwamura/AP
Investors are fearful. They shouldn’t be
People walk past the New York Stock Exchange (NYSE) on March 28, 2024 in New York City.
NDZ/STAR MAX/IPx/AP
What stalled this year’s seemingly infallible stock market rally